Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies

CM Venema, LH Mammatas, CP Schröder… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment…

Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care

LH Mammatas, HMW Verheul, NH Hendrikse… - Cellular Oncology, 2015 - Springer
Introduction Molecular imaging has been defined as the visualization, characterization and
measurement of biological processes at the molecular and cellular level in humans and other …

Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients

…, JM van der Bol, LH Mammatas… - JAMA Network …, 2023 - jamanetwork.com
Importance Although older patients are at increased risk of developing grade 3 or higher
chemotherapy-related toxic effects, no studies, to our knowledge, have focused on the …

[HTML][HTML] Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study

LH Mammatas, CM Venema, CP Schröder… - EJNMMI research, 2020 - Springer
Purpose Correct identification of tumour receptor status is important for treatment decisions
in breast cancer. [ 18 F]FES PET and [ 18 F]FDHT PET allow non-invasive assessment of the …

[HTML][HTML] Diagnostic Performance of [18F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer

R Iqbal, LH Mammatas, T Aras, WV Vogel… - Diagnostics, 2021 - mdpi.com
Positron emission tomography using [ 18 F]fluorodeoxyglucose (FDG PET) potentially
underperforms for staging of patients with grade 1–2 estrogen receptor positive (ER+) breast …

[HTML][HTML] Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study

LH Mammatas, AS Zandvliet, M Rovithi… - Cancer Chemotherapy …, 2020 - Springer
… were up to 204 mg/L/h (SD ± 113 mg/L/h) with a C max up to 21.0 mg/L (SD ± 11 mg/L),
reached at median 7 h after ingestion (range 1–12 h). The plasma concentration time curves of …

Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.

CM Venema, LH Mammatas, M van Kruchten… - 2016 - ascopubs.org
11553 Background: The ER, PR and HER2 expression is routinely determined in breast
cancer patients for prognosis and treatment decision-making. The androgen receptor (AR) is …

11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy

LH Mammatas, M Yaqub, NH Hendrikse… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potential
toxicity. Currently, no predictive biomarkers are available. The purpose of this study was …

FDG PET and FES PET Predict PFS on Endocrine Therapy

LH Mammatas, EJ van Helden, HMW Verheul… - Clinical Cancer …, 2018 - AACR
With great interest, we read the article by Kurland and colleagues (1) that investigates the
value of 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET for the prediction of …

Abstract P3-02-11: Towards a new standard for staging: A comparative study of [18F] FES PET/CT vs [18F] FDG PET/CT in patients with clinical stage II/III and …

R Iqbal, EC Bonjer, A van Zweeden, LH Mammatas… - Cancer Research, 2022 - AACR
Introduction: Accurate staging of patients with locally advanced breast cancer or locoregional
recurrent (LRR) breast cancer is essential for providing a tailored treatment. According to …